A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β₂-Agonist (LABA) Combinations in COPD.

ABSTRACT:

Introduction

Comparative data on the efficacies of long-acting muscarinic antagonist (LAMA) and long-acting β₂-agonist (LABA) combinations for the treatment of moderate-to-very-severe chronic obstructive pulmonary disease (COPD) are limited. The aim of this Bayesian network meta-analysis (NMA) is to assess the relative efficacies of available open combinations (delivered via separate inhalers) and fixed-dose combinations (FDCs, delivered via a single inhaler).

Methods

We conducted a systematic literature review with the aim of identifying randomized controlled trials (RCTs) of ≥8-week duration in adults aged ≥40 years with COPD that compared LAMA + LABA combinations with each other, with tiotropium (TIO), or with placebo. Data on changes from baseline in trough fo

SUBMITTER: Sion KYJ 

PROVIDER: S-EPMC6964204 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature